2 results
Approved WMOCompleted
Primary objective: To demonstrate a clinically significant improvement in morning FEV1 in moderate to severe allergic asthmatics inadequately controlled by ICS therapy treated with QAW039 for 12 weeks compared to placebo.Secondary objectives:…
Approved WMOCompleted
Primary Objective: To evaluate the effect of solriamfetol on cognitive functioning using an objective measurement. Secondary Objective:To evaluate the effect of solriamfetol on cognitive functioning using a subjective endpoint